Hyperfine Future Growth

Future criteria checks 1/6

Hyperfine is forecast to grow earnings and revenue by 18.4% and 17.5% per annum respectively while EPS is expected to grow by 18.8% per annum.

Key information

18.4%

Earnings growth rate

18.8%

EPS growth rate

Medical Equipment earnings growth	16.2%
Revenue growth rate	17.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	09 Apr 2024

Recent future growth updates

Recent updates

Hyperfine appoints Maria Sainz as President, CEO

Oct 06

Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M

Aug 10

Earnings and Revenue Growth Forecasts

NasdaqGM:HYPR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	20	-32	N/A	N/A	2
12/31/2025	16	-36	-39	-33	2
12/31/2024	13	-37	-43	-39	3
12/31/2023	11	-44	-43	-42	N/A
9/30/2023	10	-47	-48	-47	N/A
6/30/2023	10	-49	-52	-51	N/A
3/31/2023	8	-62	-59	-59	N/A
12/31/2022	7	-73	-73	-72	N/A
9/30/2022	6	-86	-77	-75	N/A
6/30/2022	4	-89	-75	-72	N/A
3/31/2022	3	-81	-70	-67	N/A
12/31/2021	1	-65	-50	-47	N/A
9/30/2021	1	-46	-39	-37	N/A
6/30/2021	1	-35	-34	-32	N/A
3/31/2021	1	-26	-26	-25	N/A
12/31/2020	0	-23	-23	-22	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HYPR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HYPR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HYPR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HYPR's revenue (17.5% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: HYPR's revenue (17.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if HYPR's Return on Equity is forecast to be high in 3 years time

Hyperfine Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Hyperfine, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Hyperfine, Inc. Provides Earnings Guidance for the Full Year 2023

Hyperfine, Inc. Provides Earnings Guidance for the Year 2023

Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022

Consensus forecasts updated

Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022

Recent updates

Hyperfine, Inc. to Report Q1, 2024 Results on May 13, 2024

Hyperfine, Inc., Annual General Meeting, Jun 11, 2024

Hyperfine, Inc. Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in Care PMR Study

Hyperfine, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Hyperfine, Inc. Launches AI-Powered Brain Imaging Software for Enhanced Image Quality and Ease of Use

Hyperfine, Inc. Provides Earnings Guidance for the Full Year 2023

Hyperfine, Inc. Completes Enrollment for Hope Pmr Pediatric Hydrocephalus Study Using Hyperfine, Inc. Portable Mr. Imaging System

Hyperfine, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Hyperfine, Inc. Announces Executive Changes

Hyperfine, Inc. Provides Earnings Guidance for the Year 2023

Hyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop Portable MR Imaging System

Hyperfine, Inc. Announces New Data Regarding the Use of the Swoop System in Stroke Patient Follow-Up

Hyperfine, Inc. Announces Chief Financial Officer Changes

Hyperfine, Inc. Announces Termination of Neela Paykel as General Counsel, Chief Compliance Officer, and Corporate Secretary

Hyperfine Notifies the Nasdaq Listing Qualifications Staff

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022

Hyperfine, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Hyperfine Names Maria Sainz as Chief Executive Officer, Effective October 24, 2022

Hyperfine appoints Maria Sainz as President, CEO

Consensus forecasts updated

Founder & Vice Chairman recently bought US$442k worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Hyperfine, Inc. Provides Revenue Guidance for the Full Year of 2022

Hyperfine GAAP EPS of -$0.33 misses by $0.06, revenue of $1.53M misses by $0.47M

Hyperfine, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Hyperfine, Inc. Announces Zero Radiation Dose Rapid MR Imaging Test for Pediatric Hydrocephalus Patients

Hyperfine, Inc. Announces Executive Changes, Effective July 29, 2022

Hyperfine stock plunges 14% as CEO Dave Scott steps down

Founder & Vice Chairman recently bought US$119k worth of stock

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Hyperfine, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

Hyperfine, Inc., Annual General Meeting, Jun 08, 2022

Hyperfine, Inc. to Report Q1, 2022 Results on May 11, 2022

Hyperfine (NASDAQ:HYPR) Is In A Good Position To Deliver On Growth Plans

Hyperfine: MR Imaging In A Swoop

Hyperfine, Inc. to Report Q4, 2021 Results on Mar 23, 2022

Hyperfine Appoints Chip Truwit, M.D. as Senior Medical Director

Hyperfine, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Hyperfine, Inc. announced a financing transaction

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies